Holen Sie sich die Stockscreener-App
1.23
2.38%
-0.03
Schlusskurs vom Vortag:
$1.26
Offen:
$1.25
24-Stunden-Volumen:
244.84K
Relative Volume:
1.18
Marktkapitalisierung:
$156.53M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-18.43M
KGV:
-7.8947
EPS:
-0.1558
Netto-Cashflow:
$-12.87M
1W Leistung:
-6.11%
1M Leistung:
+6.03%
6M Leistung:
-13.99%
1J Leistung:
-16.33%
1-Tages-Spanne:
$1.20
$1.28
1-Wochen-Bereich:
$1.13
$1.32
52-Wochen-Spanne:
$1.04
$2.60
Tiziana Life Sciences Ltd Stock (TLSA) Company Profile
Firmenname
Tiziana Life Sciences Ltd
Sektor
Branche
Telefon
-
Adresse
-
Compare TLSA vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
TLSA
Tiziana Life Sciences Ltd
|
1.23 | 156.53M | 0 | -18.43M | -12.87M | -0.1558 |
VRTX
Vertex Pharmaceuticals Inc
|
485.39 | 123.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
664.52 | 69.67B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.62 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
298.76 | 39.89B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
186.88 | 39.73B | 742.00K | -1.37B | -1.07B | -7.0731 |
Tiziana Life Sciences Ltd Stock (TLSA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2020-12-22 | Eingeleitet | B. Riley Securities | Buy |
| 2018-12-17 | Eingeleitet | Laidlaw | Buy |
Tiziana Life Sciences Ltd Aktie (TLSA) Neueste Nachrichten
Enterprise value to EBITDA forward of Tiziana Life Sciences Ltd – NASDAQ:TLSA - TradingView
Price to book forward of Tiziana Life Sciences Ltd – NASDAQ:TLSA - TradingView
Price to sales forward of Tiziana Life Sciences Ltd – NASDAQ:TLSA - TradingView
Tiziana Life Sciences Ltd. Actuals & Estimates (DUS:0RP) - TradingView
Tiziana Life Sciences Ltd. Actuals & Estimates (NASDAQ:TLSA) - TradingView
Tiziana Life Sciences Ltd. Actuals & Estimates (FWB:0RP) - TradingView
TLSA Forecast — Price Target — Prediction for 2027 - TradingView
Tiziana Life Sciences Ltd. Actuals & Estimates (TRADEGATE:0RP) - TradingView
Small cap wrap: Power Metallic Mines, Tiziana Life Sciences, Fox Tungsten, American Resources… - Proactive financial news
0RP Forecast — Price Target — Prediction for 2027 - TradingView
Could Intranasal Innovation Shape the Future of Multiple Sclerosis Care? - Kalkine Media
Tiziana Life Sciences doses last patient in Phase 2a multiple sclerosis trial - Yahoo! Finance Canada
Tiziana Life Sciences (TLSA) Advances Clinical Trial for Multiple Sclerosis Treatment - GuruFocus
Tiziana Life Sciences Doses Last Patient in Phase 2 Trial of Potential Multiple Sclerosis Treatment - Moomoo
symbol__ Stock Quote Price and Forecast - CNN
Tiziana (Nasdaq: TLSA) completes enrollment in Phase 2a INFORM-MS study - Stock Titan
Tiziana Life Sciences Ltd. - Via Ritzau
Tiziana Life Sciences Ltd (TLSA) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Tiziana Life Sciences Ltd (TLSA) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Tiziana Life Sciences Ltd (TLSA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Tiziana Life Sciences Ltd (TLSA) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Why Tiziana Life Sciences Is Back on the Small-Cap Radar? - Kalkine Media
Tiziana Life Sciences Ltd (TLSA) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Tiziana Life Sciences Ltd (TLSA) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Tiziana Life Sciences Ltd (TLSA) Valuation: PE, PB & Fair Value Analysis - TradingKey
Tiziana Life Sciences Ltd (TLSA) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Tiziana Life Sciences Ltd (TLSA) Institutional Confidence - TradingKey
Tiziana Life Sciences (TLSA) insider awarded 15,000 common shares - Stock Titan
Tiziana Life Sciences Chair Boosts Stake as Foralumab Trials Advance - The Globe and Mail
Tiziana Life Sciences Ltd announced that it has received $0.01665 million in funding - marketscreener.com
Tiziana Life Sciences (TLSA) Executive Chairman Boosts Stake wit - GuruFocus
Tiziana Life Sciences (TLSA) Executive Chairman Boosts Shareholding - GuruFocus
Tiziana executive chairman increases stake - Proactive financial news
Tiziana Life Sciences Announces Purchase of Shares by Executive Chairman - The Manila Times
Tiziana (NASDAQ: TLSA) chair lifts stake with 15,000-share purchase - Stock Titan
Founder now owns 34.89% of Tiziana Life Sciences after 15K-share buy - Stock Titan
Tiziana Life Sciences (TLSA) Retreats 2.6% as Shares Approach Key SupportGolden Cross - newsline.com
[6-K] Tiziana Life Sciences Ltd Current Report (Foreign Issuer) | TLSA SEC FilingForm 6-K - Stock Titan
Tiziana Life Sciences to Present at the Jefferies Global Healthcare Conference in New York - NTB Kommunikasjon
Tiziana Life Sciences to present clinical updates at Jefferies healthcare conference - Proactive financial news
Biotech Tiziana to brief investors on clinical updates at Jefferies event - Stock Titan
Tiziana Life Sciences (TLSA) Slips 2.65% as Stock Tests Key Support ZoneVolume Oscillator - The Legal Advocate
TLSATiziana Life Sciences Ltd Stock Price and Quote - Finviz
Tiziana Life Sciences advances foralumab program with full Phase 2 enrollment and encouraging expanded access data – ICYMI - Proactive financial news
Tiziana Life Sciences (TLSA) COO discloses Form 3 share and option holdings - Stock Titan
Tiziana Life Sciences completes enrollment in Phase 2a trial for multiple sclerosis drug foralumab - Pluang
Tiziana Life Sciences (TLSA) Completes Patient Enrollment in Cli - GuruFocus
Tiziana completes enrollment for Phase 2 trial in progressive MS study - Proactive financial news
Why Is TLSA Stock Rising Today? - Stocktwits
Tiziana Life Sciences completes enrollment in Phase 2a multiple sclerosis trial - Yahoo! Finance Canada
Tiziana Fully Enrolls its Phase 2 Placebo Controlled Multiple Sclerosis Trial - The Manila Times
Finanzdaten der Tiziana Life Sciences Ltd-Aktie (TLSA)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.64%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):